Predicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancer

Personalized Medicine

Volumn 9, Issue 8, 2012, Pages 879-887

  Petera, Jiří ^a   Sirák, Igor ^a   Tuček, Luboš ^a   Hodek, Miroslav ^a   Paluska, Petr ^a   Kašaová, Linda ^a   Paulíková, Simona ^a   Vošmik, Milan ^a   Doležalová, Helena ^a   Cvanova, Michaela ^b   Halamka, Magdalena ^c   Laco, Jan ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

high dose rate brachytherapy; oral cancer; predictive factors; VEGF

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN KU 80; PROTEIN P16; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUTH CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84869755036     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.95     Document Type: Article

References (38)

1. Guinot JL, Dantos M, Tortahada MI et al. Efficacy of highYdose-rate interstitial brachytherapy in patients with oral tongue carcinoma. Brachytherapy 9, 227Y 234 (2010).
2. Fujita M, Hirokawa Y, Kashiwado K et al. Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: Factors influencing local control and soft tissue complications. Int. J. Radiat. Oncol. Biol. Phys. 44, 767-775 (1999). (Pubitemid 29284125)
3. Benk V, Mazeron JJ, Grimad L et al. Comparison of curietherapy versus external irradiation combined with curietherapy in stage II squamous cell carcinomas of the mobile tongue. Radiother. Oncol. 18, 339-347 (1990). (Pubitemid 20264679)
4. Vandenbrouck C, Sancho-Garnier H, Chassagne D, Saravane D, Cachin Y, Micheau C. Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: Results of randomized clinical trial. Cancer 46, 386-390 (1980). (Pubitemid 10085956)
5. Pernot M, Aletti P, Carolus I et al. Indications, techniques and results of postoperative brachytherapy in cancer of the oral cavity. Radiother. Oncol. 35, 186-192 (1995).
6. Harris SL, Thorne LB, Seaman WT et al. Association of p16ink4a overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck 33, 1622-1627 (2011).
7. Shah NG, Trivedi TI, Tankshali RA et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: A multivariate analysis. Head Neck 31, 1544-1556 (2009).
8. Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int. J. Cancer 120, 1731-1738 (2007). (Pubitemid 46399359)
9. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62, 7350-7356 (2002). (Pubitemid 36025259)
10. Tse GM, Yu KH, Chan AW et al. HER2 expression predicts improved survival in patients with cervical node positive head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 141, 467-473 (2009).
11. Dubois RN, Abramson SB, Crofford L et al. Cylooxygenase in biology and disease. FASEB J. 12, 1063-1073 (1998).
12. Milas L. Cyclooxygenase-2 (COX 2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol. 11, 290-299 (2001). (Pubitemid 32959664)
13. Garg AK, Jhingran A, Klopp AH et al. Expression of nuclear transcription factor kB in locally advanced human cervical cancer treated with definitive chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 78, 1331-1336 (2010).
14. Nariai Y, Mishima K, Yoshimura Y, Sekine J. FAP-1 and NF kB expressions in oral squamous cell carcinoma as potential for chemo-radio sensitivity and prognosis. Int. J. Oral Maxillofac. Surg. 40, 419-426 (2011).
15. Chang HW, Kim SY, Yi SL et al. Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck cancers. Oral Oncol. 42, 979-986 (2006). (Pubitemid 44573883)
16. Harima Y, Sawada S, Miyazaki Y et al. Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. Am. J. Clin. Oncol. 26, 80-85 (2003).
17. Eckert AW, Schutze A, Lautner MH et al. HIF 1a is a prognostic marker in oral squamous cell carcinomas. Int. J. Biol. Markers 25, 87-92 (2010).
18. Seki S, Fujiwara M, Matsuura M et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Oral Oncol. 47, 588-593 (2011).
19. Sugiura T, Inoue Y, Matsuki R et al. VEGF C and VEGF D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: IMPLICATIONS for use as a prognostic marker. Int. J. Oncol. 34, 673-680 (2009).
20. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8(4), 138-140 (1987).
21. Guedea F, Ventura M, Polo A et al. Patterns of care for brachytherapy in Europe (PC BE) in Spain and Poland: Comparative results. Rep. Pract. Oncol. Radiother. 12, 39-45 (2007). (Pubitemid 46663390)
22. Moskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high dose rate brachytherapy boost for localised prostate cancer. Radiother. Oncol. 103, 217-222 (2012).
23. Polgar C, Major T, Fodor J et al. High dose rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: Seven years results of a comparative study. Int. J. Radiat. Oncol. Biol. Phys. 60, 1173Y 1181 (2004). (Pubitemid 39440803)
24. Mazeron JJ, Ardier JM, Haie-Méder C et al. GECYESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother. Oncol. 91, 150-156 (2009).
25. Wendt CD, Peters LJ, Declos L et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: Importance of the proportions of therapy delivered with interstitial therapy. Int. J. Radiat. Oncol. Biol. Phys. 18, 1287-1292 (1990). (Pubitemid 20234137)
26. Grabenbauer GG, Rödel C, Brunner T et al. Interstitial brachytherapy with Ir 192 low dose rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Strahlenther. Onkol. 7, 338-344 (2001). (Pubitemid 32673153)
27. Lapeyre M, Hoffstetter S, Peifert D et al. Postoperative brachytherapy alone for T1-2 N0 squamous cell carcinomas of the oral tongue and floor of mouth with close or positive margins. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 37-42 (2000). (Pubitemid 30488210)
28. Nakagawa T, Shibuya H, Yoshimura R et al. Neck node metastasis after successful brachytherapy for early stage tongue carcinoma. Radiother. Oncol. 68, 129-135 (2003). (Pubitemid 38367545)
29. Williamson JF, Brenner DJ. Physics and biology of brachytherapy. In: RADIATION Oncology. Perez CA, Halperin EC, Brady LW (Eds). Lippincott Williams & Wilkins, PA, USA (2008).
30. Tucek L, Petera J, Sirak I et al. Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer. Rep. Pract. Oncol. Radiother. 16, 239-243 (2011).
31. Chakrabarti B, Ghorai S, Basu B et al. Late nodal metastasis in early-stage node-negative oral cavity cancers after successful sole interstitial brachytherapy: An institutional experience of 42 cases in India. Brachytherapy 9, 254-259 (2010).
32. Naruse T, Kawasaki G, Yanamoto S et al. Immnohistochemical study of VEGF expresson in oral squamous cell carcinomas: Correlation with the mTORYHIF 1a pathway. Anticancer Res. 12, 4429-4437 (2011).
33. Shang ZJ, Li JR, Li ZB. Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J. Oral Maxillofac. Surg. 65, 17-21 (2007).
34. Shang ZJ, Li ZB, Li Jr. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: In vitro and in vivo studies. Int. J. Oral Maxillofac. Surg. 35, 533-538 (2006).
35. Asakage T, Yokose T, Mukai K et al. Tumour thickness predicts cervical metastasis in patients with stage I/II carcinoma of the tongue. Cancer 82, 1443-1448 (1998). (Pubitemid 28164987)
36. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: Means, markers and perspectives (II). Oral Oncol. 46, 636-643 (2010).
37. Watanabe H, Mogushi K, Miura M et al. Prediction of lymphatic metastasis based on gene expression profile analysis after brachytherapy for early-stage oral tongue carcinoma. Radiother. Oncol. 87, 237-242 (2008).
38. Woolgar JA. Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol. 42, 229-239 (2006 (Pubitemid 43246755)